25-hydroxyvitamin D Levels and chronic kidney disease in the AusDiab (Australian Diabetes, Obesity and Lifestyle) study

BMC Nephrology

Volumn 13, Issue 1, 2012, Pages

  Damasiewicz, Matthew J ^a,b   Magliano, Dianna J ^c   Daly, Robin M ^d,g   Gagnon, Claudia ^e,g   Lu, Zhong X ^f   Ebeling, Peter R ^g   Chadban, Steven J ^h,i   Atkins, Robert C ^c   Kerr, Peter G ^a,b   Shaw, Jonathan E ^c   Polkinghorne, Kevan R ^a,b  

^a MONASH MEDICAL CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d DEAKIN UNIVERSITY   (Australia)

^e Université Laval   (Canada)

^f MELBOURNE PATHOLOGY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁱ UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Albuminuria; and Vitamin D; Chronic kidney disease; Glomerular filtration rate

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; CREATININE;

ADULT; AGED; ALBUMINURIA; ARTICLE; AUSTRALIA; CHRONIC KIDNEY DISEASE; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; ENZYME ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; URINALYSIS;

ADULT; AGED; ALBUMINURIA; AUSTRALIA; BIOLOGICAL MARKERS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; FEMALE; HUMANS; LIFE STYLE; MALE; MIDDLE AGED; OBESITY; POPULATION SURVEILLANCE; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84863201290     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-13-55     Document Type: Article

References (51)

1. Update in vitamin D. Adams JS, Hewison M, J Clin Endocrinol Metab 2010 95 2 471 478 10.1210/jc.2009-1773 20133466
2. Vitamin D deficiency. Holick MF, N Engl J Med 2007 357 3 266 281 10.1056/NEJMra070553 17634462 (Pubitemid 47080391)
3. Prevalence of chronic kidney disease in the United States. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS, JAMA 2007 298 17 2038 2047 10.1001/jama.298.17.2038 17986697 (Pubitemid 350074801)
4. Association of oral calcitriol with improved survival in nondialyzed CKD. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B, J Am Soc Nephrol 2008 19 8 1613 1619 10.1681/ASN.2007111164 18463168
5. Oral active vitamin D is associated with improved survival in hemodialysis patients. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andia JB, Kidney Int 2008 74 8 1070 1078 10.1038/ki.2008.343 18633342
6. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA, Thadhani R, J Am Soc Nephrol 2005 16 4 1115 1125 10.1681/ASN.2004070573 15728786 (Pubitemid 41710323)
7. Vitamin D levels and early mortality among incident hemodialysis patients. Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA, Tonelli M, et al. Kidney Int 2007 72 8 1004 1013 10.1038/sj.ki.5002451 17687259 (Pubitemid 47530570)
8. New vitamin D analogs and changing therapeutic paradigms. Cunningham J, Zehnder D, Kidney Int 2011 79 7 702 707 10.1038/ki.2010.387 20962748
9. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J, J Steroid Biochem Mol Biol 2004 89-90 1-5 387 392 22154810 (Pubitemid 38844316)
10. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC, Am J Physiol Endocrinol Metab 2006 291 2 315 E322 10.1152/ajpendo.00590.2005 16507601 (Pubitemid 44035291)
11. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: The Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Tomaschitz A, Pilz S, Ritz E, Grammer T, Drechsler C, Boehm BO, Marz W, Clin Chim Acta 2010 411 17-18 1354 1360 20515678
12. Renoprotective effects of vitamin D analogs. Li YC, Kidney Int 2010 78 2 134 139 10.1038/ki.2009.175 19471320
13. Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G, Kidney Int 1998 53 5 1209 1216 10.1046/j.1523-1755. 1998.00874.x 9573535 (Pubitemid 28316881)
14. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, et al. Jama 2001 286 4 421 426 10.1001/jama.286.4.421 11466120 (Pubitemid 32681484)
15. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, Kusek JW, Rogers NL, Teschan PE, Kidney Int 1997 51 6 1908 1919 10.1038/ki.1997.260 9186882 (Pubitemid 27252762)
16. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS, Am J Kidney Dis 2007 50 1 69 77 10.1053/j.ajkd.2007.04.015 17591526 (Pubitemid 46962855)
17. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P, J Am Soc Nephrol 2009 20 12 2631 2639 10.1681/ASN.2009030283 19875805
18. Serum 25-hydroxyvitamin D and change in estimated glomerular filtration rate. de Boer IH, Katz R, Chonchol M, Ix JH, Sarnak MJ, Shlipak MG, Siscovick DS, Kestenbaum B, Clin J Am Soc Nephrol 2011 6 9 2141 2149 10.2215/CJN.02640311 21836148
19. Vitamin D deficiency, inflammation, and albuminuria in chronic kidney disease: complex interactions. Isakova T, Gutierrez OM, Patel NM, Andress DL, Wolf M, Levin A, J Ren Nutr 2011 21 4 295 302 10.1053/j.jrn.2010.07.002 20817560
20. Vitamin D levels and patient outcome in chronic kidney disease. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C, Kidney Int 2009 75 1 88 95 10.1038/ki.2008.501 18843258
21. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Mehrotra R, Kermah DA, Salusky IB, Wolf MS, Thadhani RI, Chiu YW, Martins D, Adler SG, Norris KC, Kidney Int 2009 76 9 977 983 10.1038/ki.2009.288 19657329
22. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Pilz S, Iodice S, Zittermann A, Grant WB, Gandini S, Am J Kidney Dis 2011 58 3 374 382 21636193
23. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)-methods and response rates. Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, de Courten M, Jolley D, McCarty DJ, Diabetes Res Clin Pract 2002 57 2 119 129 10.1016/S0168-8227(02)00025-6 12062857 (Pubitemid 34626451)
24. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Polkinghorne KR, Su Q, Chadban SJ, Shaw JE, Zimmet PZ, Atkins RC, Am J Kidney Dis 2006 47 4 604 613 10.1053/j.ajkd.2005. 12.034 16564938
25. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Magliano DJ, Barr EL, Zimmet PZ, Cameron AJ, Dunstan DW, Colagiuri S, Jolley D, Owen N, Phillips P, Tapp RJ, et al. Diabetes Care 2008 31 2 267 272 17989310 (Pubitemid 351213333)
26. Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5years: results from a national, population-based prospective study (the Australian Diabetes, Obesity and Lifestyle study). Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Shaw JE, Zimmet PZ, Sikaris K, Grantham N, Ebeling PR, Daly RM, Diabetes Care 2011 34 5 1133 1138 10.2337/dc10-2167 21430082
27. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, J Clin Endocrinol Metab 2011 96 7 1911 1930 10.1210/jc.2011-0385 21646368
28. Vitamin D and adult bone health in Australia and New Zealand: a position statement. Med J Aust 2005 182 6 281 285 15777143
29. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007 49 2 Suppl 2 12 S154 17276798
30. A new equation to estimate glomerular filtration rate. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, et al. Ann Intern Med 2009 150 9 604 612 19414839
31. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 39 2 Suppl 1 1 S266 11904577
32. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y, J Am Soc Nephrol 2009 20 9 1997 2008 10.1681/ASN.2009010019 19628668
33. Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. He W, Kang YS, Dai C, Liu Y, J Am Soc Nephrol 2011 22 1 90 103 10.1681/ASN.2009121236 21030600
34. Vitamin D: roles in renal and cardiovascular protection. Li YC, Curr Opin Nephrol Hypertens 2012 21 1 72 79 10.1097/MNH.0b013e32834de4ee 22143249
35. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP, J Clin Invest 2002 110 2 229 238 12122115 (Pubitemid 34787360)
36. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. Tan X, Li Y, Liu Y, J Am Soc Nephrol 2006 17 12 3382 3393 10.1681/ASN.2006050520 17082242 (Pubitemid 44865281)
37. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, et al. Am J Pathol 2001 158 5 1733 1741 10.1016/S0002-9440(10)64129-6 11337371 (Pubitemid 32422938)
38. Combination therapy with an angiotensin-converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. Mizobuchi M, Morrissey J, Finch JL, Martin DR, Liapis H, Akizawa T, Slatopolsky E, J Am Soc Nephrol 2007 18 6 1796 1806 10.1681/ASN.2006091028 17513326 (Pubitemid 46870316)
39. Analogs of 1alpha,25-dihydroxyvitamin D(3) as novel inhibitors of renin biosynthesis. Qiao G, Kong J, Uskokovic M, Li YC, J Steroid Biochem Mol Biol 2005 96 1 59 66 10.1016/j.jsbmb.2005.02.008 15878826 (Pubitemid 41080519)
40. Renin-angiotensin-aldosterone system and progression of renal disease. Ruster C, Wolf G, J Am Soc Nephrol 2006 17 11 2985 2991 10.1681/ASN.2006040356 17035613 (Pubitemid 44707758)
41. Transcription factor-kappa B (NF-kappa B) and renal disease. Guijarro C, Egido J, Kidney Int 2001 59 2 415 424 10.1046/j.1523-1755.2001.059002415.x 11168923 (Pubitemid 32157906)
42. Oral cholecalciferol decreases albuminuria and urinary TGF-beta1 in patients with type 2 diabetic nephropathy on established renin-angiotensin- aldosterone system inhibition. Kim MJ, Frankel AH, Donaldson M, Darch SJ, Pusey CD, Hill PD, Mayr M, Tam FW, Kidney Int 2011 80 8 851 860 10.1038/ki.2011.224 21832985
43. Monocyte chemoattractant protein-1-induced tissue inflammation is critical for the development of renal injury but not type 2 diabetes in obese db/db mice. Chow FY, Nikolic-Paterson DJ, Ma FY, Ozols E, Rollins BJ, Tesch GH, Diabetologia 2007 50 2 471 480 10.1007/s00125-006-0497-8 17160673
44. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Zehnder D, Quinkler M, Eardley KS, Bland R, Lepenies J, Hughes SV, Raymond NT, Howie AJ, Cockwell P, Stewart PM, et al. Kidney Int 2008 74 10 1343 1353 10.1038/ki.2008.453 18784644
45. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Szeto CC, Chow KM, Kwan BC, Chung KY, Leung CB, Li PK, Am J Kidney Dis 2008 51 5 724 731 10.1053/j.ajkd.2007.12.038 18436082 (Pubitemid 351626254)
46. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, et al. Lancet 2010 376 9752 1543 1551 10.1016/S0140-6736(10)61032-X 21055801
47. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Dusso AS, Tokumoto M, Kidney Int 2011 79 7 715 729 10.1038/ki.2010.543 21270766
48. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Chonchol M, Scragg R, Kidney Int 2007 71 2 134 139 10.1038/sj.ki.5002002 17082756 (Pubitemid 46094686)
49. Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. White SL, Polkinghorne KR, Atkins RC, Chadban SJ, Am J Kidney Dis 2010 55 4 660 670 10.1053/j.ajkd.2009.12.011 20138414
50. The role of cystatin C in improving GFR estimation in the general population. Eriksen BO, Mathisen UD, Melsom T, Ingebretsen OC, Jenssen TG, Njolstad I, Solbu MD, Toft I, Am J Kidney Dis 2012 59 1 32 40 10.1053/j.ajkd.2011.09.001 22001180
51. Tracking of serum 25-hydroxyvitamin D levels during 14years in a population-based study and during 12months in an intervention study. Jorde R, Sneve M, Hutchinson M, Emaus N, Figenschau Y, Grimnes G, Am J Epidemiol 2010 171 8 903 908 10.1093/aje/kwq005 20219763